At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses recent advances in the management of patients with mantle cell lymphoma (MCL). Rituximab maintenance after autologous haematopoietic stem cell transplantation resulted in prolonged progression-free survival. Ibrutinib is being considered for frontline treatment in MCL.